# Becton Dickinson & Co (BDX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/becton-dickinson-and-co/ JSON: https://steadybase.io/company/becton-dickinson-and-co.json Checked Nov 10, 2026. Latest filing read: Aug 6, 2026.

## Company

- Legal name: BECTON DICKINSON & CO
- Ticker: BDX (NYSE)
- SEC CIK: 0000010795
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Franklin Lakes, NJ
- Fiscal year ends: September 30
- SEC filer category: Large accelerated filer
- Website: bd.com
- Investor relations: https://investors.bd.com/
- LinkedIn: https://www.linkedin.com/company/bd1
- Next earnings date: Feb 4, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $21.8B for the fiscal year ended Sep 30, 2025 (10-K filed Nov 25, 2025). Source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/0000010795-25-000099-index.html
- Operating income: $2.6B for the fiscal year ended Sep 30, 2025 (10-K filed Nov 25, 2025). Source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/0000010795-25-000099-index.html
- Net income: $1.7B for the fiscal year ended Sep 30, 2025 (10-K filed Nov 25, 2025). Source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/0000010795-25-000099-index.html
- SG&A: $5.3B for the fiscal year ended Sep 30, 2025 (10-K filed Nov 25, 2025). Source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/0000010795-25-000099-index.html
- Employees: 72,000 as of Sep 30, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- Shares outstanding: 272,386,800 as of Jun 30, 2026 (10-Q filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/10795/000001079526000035/0000010795-26-000035-index.html
- Auditor: Ernst & Young LLP, New York, New York, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm

## Business

Becton, Dickinson and Company (also referred to herein as "BD") was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. BD’s executive offices are located at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, and its telephone number is (201) 847-6800. All references in this Form 10-K to "BD", "the Company", "we", "our" or "us" refer to Becton, Dickinson and Company and its domestic and foreign subsidiaries, unless otherwise indicated by the context.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Sep 30, 2025 | $21.8B | $2.6B | $1.7B | $5.3B |
| Sep 30, 2024 | $20.2B | $2.4B | $1.7B | $4.9B |
| Sep 30, 2023 | $19.4B | $2.1B | $1.5B | $4.7B |
| Sep 30, 2022 | $18.9B | $2.3B | $1.8B | $4.7B |
| Sep 30, 2021 | $19.1B | $2.3B | $2.1B | $4.7B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/becton-dickinson-and-co.json

## Officers and directors

- Thomas E. Polen Jr, Chairman, CEO and President. Source: Form 4 filed Aug 14, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026057166/0001628280-26-057166-index.htm
- Vitor Roque, EVP & Chief Financial Officer. LinkedIn: https://linkedin.com/in/vitor-roque-76994b9. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026060580/0001628280-26-060580-index.htm
- Christopher DelOrefice, EVP & Chief Financial Officer. Source: Form 4 filed Dec 1, 2025, https://www.sec.gov/Archives/edgar/data/10795/000162828025054346/0001628280-25-054346-index.htm
- Christopher J. DelOrefice, Executive Vice President and Chief Financial Officer. Source: 10-K filed Nov 25, 2025, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- Michael Feld, EVP, Chief Revenue Officer. Source: Form 4 filed Sep 29, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026063882/0001628280-26-063882-index.htm
- Roland Goette, EVP and President, EMEA. Source: Form 4 filed Aug 12, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026056366/0001628280-26-056366-index.htm
- Bilal Muhsin, EVP & President Connected Care. LinkedIn: https://linkedin.com/in/bilal-muhsin-b59999b. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026047193/0001628280-26-047193-index.htm
- Michael David Garrison, EVP & Pres Med.Essntl&BioPharm. Source: Form 4 filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026045374/0001628280-26-045374-index.htm
- Manish Sinha, EVP and Chief People Officer. LinkedIn: https://linkedin.com/in/sinhamanishmr. Source: Form 3 filed Jun 22, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026044647/0001628280-26-044647-index.htm
- Peter Menziuso, EVP and President, BDI. LinkedIn: https://linkedin.com/in/petermenziuso. Source: Form 4 filed Jun 2, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026039738/0001628280-26-039738-index.htm
- Shana Carol Neal, EVP and Chief People Officer. Source: Form 4 filed Apr 6, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026023944/0001628280-26-023944-index.htm
- Lanesha Minnix, EVP and General Counsel. LinkedIn: https://linkedin.com/in/laneshaminnix. Source: Form 4 filed Mar 17, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026018607/0001628280-26-018607-index.htm
- Pamela L. Spikner, SVPController & Chief Acct Off. LinkedIn: https://linkedin.com/in/pamela-spikner-0243ab13. Source: Form 4 filed Mar 4, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026014438/0001628280-26-014438-index.htm
- Massimiliano Urbini, EVP & Chief ISC Officer. Source: Form 3 filed Feb 6, 2026, https://www.sec.gov/Archives/edgar/data/10795/000162828026006032/0001628280-26-006032-index.htm
- David Shan, EVP and Chief ISC Officer. Source: Form 4 filed Jan 6, 2026, https://www.sec.gov/Archives/edgar/data/10795/000196304826000002/0001963048-26-000002-index.htm
- Pavan Kumar Mocherla, EVP & President, Greater Asia. Source: Form 4 filed Dec 1, 2025, https://www.sec.gov/Archives/edgar/data/10795/000162828025054380/0001628280-25-054380-index.htm
- Richard Byrd, EVP & President Interventional. Source: Form 4 filed Dec 1, 2025, https://www.sec.gov/Archives/edgar/data/10795/000162828025054344/0001628280-25-054344-index.htm
- Antoine C. Ezell, Executive Vice President, President of the Americas and Chief Marketing Officer. Source: 10-K filed Nov 25, 2025, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- Michael Garrison, Executive Vice President and President, Medical Segment. Source: 10-K filed Nov 25, 2025, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- Pavan Mocherla, Executive Vice President and President, Greater Asia. Source: 10-K filed Nov 25, 2025, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- Shana Neal, Executive Vice President and Chief People Officer. Source: 10-K filed Nov 25, 2025, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- Stephanie M. Kelly, Chief Securities and Governance Counsel, Corporate Secretary Dated: POWER OF ATTORNEY. Source: 10-K filed Nov 25, 2025, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- Bertram L. Scott, Board member (per proxy). Source: DEF 14A filed Dec 18, 2025, https://www.sec.gov/Archives/edgar/data/10795/000162828025057846/bdx-20251217.htm
- Carrie L. Byington, M.D., Board member (per proxy). Source: DEF 14A filed Dec 18, 2025, https://www.sec.gov/Archives/edgar/data/10795/000162828025057846/bdx-20251217.htm
- Christopher Jones, Board member (per proxy). Source: DEF 14A filed Dec 18, 2025, https://www.sec.gov/Archives/edgar/data/10795/000162828025057846/bdx-20251217.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026070511/bdx-20261105.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026053790/bdx-20260806.htm
- Jul 22, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026049103/bdx-20260719.htm
- May 29, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/bdx-20260529.htm
- May 20, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000114036126022270/ef20074240_8k.htm
- May 12, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000114036126020828/ny20072670x4_8k.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026031638/bdx-20260507.htm
- Apr 29, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000001079526000012/bdx-20260428.htm
- Apr 9, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026024472/bdx-20260406.htm
- Apr 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026023185/bdx-20260402.htm

## Insider trades (Form 4)

- Nov 5, 2026: Thomas E. Polen Jr (Chairman, CEO and President) sold 2,993 shares, about $628,530. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026072360/0001628280-26-072360-index.htm
- Oct 26, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 76 shares, about $15,058. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026067525/0001628280-26-067525-index.htm
- Sep 28, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 76 shares, about $13,961. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026063882/0001628280-26-063882-index.htm
- Aug 26, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 165 shares, about $31,101. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026059269/0001628280-26-059269-index.htm
- Aug 13, 2026: Thomas E. Polen Jr (Chairman, CEO and President) sold 4,152 shares, about $768,120. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026057166/0001628280-26-057166-index.htm
- Aug 11, 2026: Roland Goette (EVP and President, EMEA) sold 2,438 shares, about $440,888. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026056366/0001628280-26-056366-index.htm
- Jul 27, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 75 shares, about $11,785. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026049989/0001628280-26-049989-index.htm
- Jun 26, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 75 shares, about $11,460. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026045864/0001628280-26-045864-index.htm
- Jun 24, 2026: Michael David Garrison (EVP & Pres Med.Essntl&BioPharm) sold 1,100 shares, about $160,226. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026045374/0001628280-26-045374-index.htm
- Jun 10, 2026: Michael David Garrison (EVP & Pres Med.Essntl&BioPharm) sold 1,100 shares, about $166,628. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026042571/0001628280-26-042571-index.htm
- Jun 1, 2026: Thomas E. Polen Jr (Chairman, CEO and President) sold 2,764 shares, about $404,511. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026040095/0001628280-26-040095-index.htm
- May 26, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 75 shares, about $11,051. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026038382/0001628280-26-038382-index.htm
- Apr 27, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 74 shares, about $11,244. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026027731/0001628280-26-027731-index.htm
- Mar 26, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 75 shares, about $11,762. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026021644/0001628280-26-021644-index.htm
- Feb 26, 2026: Michael Feld (EVP, Chief Revenue Officer) sold 75 shares, about $13,638. Source: https://www.sec.gov/Archives/edgar/data/10795/000162828026012955/0001628280-26-012955-index.htm

## Latest filings

- 8-K filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/10795/000162828026053790/bdx-20260806.htm
- 10-K filed Nov 25, 2025: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/10795/000001079526000035/bdx-20260630.htm
- DEF 14A filed Dec 18, 2025: https://www.sec.gov/Archives/edgar/data/10795/000162828025057846/bdx-20251217.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/